Michael Mancino

CAST Program Director

University of Arkansas for Medical Sciences

faculty

PSY Psychiatry, College of Medicine

15 h-index 60 pubs 856 cited

Research Areas

Substance Abuse Treatment and Outcomes Opioid Use Disorder Treatment Mental Health Treatment and Access Behavioral Health and Interventions Pharmacological Effects and Toxicity Studies Maternal and Perinatal Health Interventions Analytical Chemistry and Chromatography Behavioral and Psychological Studies

Links

ORCID Lab Website UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Michael Mancino is a Professor in the Department of Psychiatry at the University of Arkansas for Medical Sciences, where he also directs the Center for Addiction Services and Treatment within the Psychiatric Research Institute. His research focuses on substance use disorders and related treatments.

Dr. Mancino's publications investigate various aspects of addiction treatment, including the utility of specific withdrawal paradigms, the development of analytical methods for quantifying medications used in treatment, and the impact of anxiety on treatment outcomes. His work also examines trends in stimulant use and explores interventions for opioid use disorder, such as smartphone-based support and pharmacological approaches like gabapentin and naltrexone. He has also published on buprenorphine clearance during pregnancy and its effects on neonatal outcomes.

With 60 total publications and an h-index of 15, Dr. Mancino has collaborated with researchers such as Alison Oliveto and Jeff Thostenson, both from the University of Arkansas for Medical Sciences, on numerous projects.

Research Overview

Dr. Michael J. Mancino is a Professor in the UAMS Department of Psychiatry and the program director of the Center for Addiction Services and Treatment in the Psychiatric Research Institute.

Metrics

h-index: 15
Publications: 60
Citations: 856

Selected Publications

Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone (2025) DOI
Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone. (2025) DOI
Study Protocol for Implementation of Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorder for Incarcerated Individuals (PLI-MOUD Study) (2025) DOI
A randomized clinical trial of disulfiram at higher doses for the treatment of cocaine use disorder among methadone-stabilized patients (2025) DOI
Gabapentin and D-cycloserine alone and in combination with naloxone in methadone-maintained humans responding under a naloxone novel-response discrimination procedure (2025) DOI
THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN (2024) DOI
Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021 (2024) DOI
484 A Preliminary Study on the Pharmacodynamics of Oral Cannabis Ingestion in Older Adults (2024) DOI
289 Heart Rate Variability in Opioid Use Disordered Participants Undergoing Buprenorphine-Assisted Detoxification (2023) DOI
Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial (2023) DOI
Smartphone intervention to optimize medication assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial (2023) DOI
Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program (2022) DOI
Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial (2021) DOI
Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum (2021) DOI
Clearance of buprenorphine during pregnancy and neonatal outcomes (2021) DOI

Grants & Funding

Efficacy of Carvedilol in Recently-Abstinent Psychostimulant Dependent Patients NIH/Nat. Inst. on Drug Abuse - Pass Through: Baylor College of Medicine Co-Investigator
CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University Principal Investigator
Clinical Trials Network: The Big South/West Node NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Texas Southwestern Medical Center Principal Investigator
ADAP Substance Abuse Treatment Clinic FY24 Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Human Services Principal Investigator
Expanding Infant Mental Health Services in AR Substance Abuse & Mental Health Services Administration - Pass Through: AR Dept of Human Services/Division of Aging and Adult Services Principal Investigator
University of Arkansas for Medical Sciences - Substance Abuse Treatment Clinic Arkansas Department of Health & Human Services Principal Investigator
Improving Treatment Outcomes for Prescription Opioid Dependence - Continuation - Continuation - Continuation - Continuation NIH/Nat. Inst. on Drug Abuse Co-Principal Investigator
Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence NIH Principal Investigator